Thromboprophylaxis for Hip Revision Arthroplasty: Can We Use the Recommendations for Primary Hip Surgery? A Cohort Study

The risk of thromboembolic events after hip revision arthroplasty might be higher than in primary hip arthroplasty. However, evidence regarding the use of thromboprophylaxis in revisions is scarce. The purpose of this study is to determine whether thromboprophylaxis recommendations for primary arthr...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2019
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23665
Acceso en línea:
https://doi.org/10.1177/1076029618820167
https://repository.urosario.edu.co/handle/10336/23665
Palabra clave:
Anticoagulant agent
Apixaban
Dabigatran
Enoxaparin
Fondaparinux
Rivaroxaban
Anticoagulant agent
Adult
Aged
Arthroplasty
Article
Body mass
Cohort analysis
Comparative study
Computed tomographic angiography
Controlled study
Deep vein thrombosis
Doppler flowmetry
Female
Hip arthroplasty
Hip replacement
Hip revision arthroplasty
Hip surgery
Hospitalization
Human
Lung embolism
Lung ventilation
Major clinical study
Male
Operation duration
Osteoarthritis
Prevalence
Priority journal
Retrospective study
Thrombosis prevention
Venous thromboembolism
Middle aged
Procedures
Very elderly
Adult
Aged
Aged, 80 and over
Anticoagulants
Cohort studies
Female
Humans
Male
Middle aged
Retrospective studies
Arthroplasty
Blood transfusion
Hip
Prevention and control
Reoperation
Replacement
Venous thromboembolism
replacement
hip
Arthroplasty
Rights
License
Abierto (Texto Completo)
Description
Summary:The risk of thromboembolic events after hip revision arthroplasty might be higher than in primary hip arthroplasty. However, evidence regarding the use of thromboprophylaxis in revisions is scarce. The purpose of this study is to determine whether thromboprophylaxis recommendations for primary arthroplasty produce similar results in hip revision arthroplasty. This comparative cohort study retrospectively analyzed consecutive patients undergoing primary hip arthroplasty and hip revision surgery between March 2004 and December 2015, who received thromboprophylaxis according to local clinical practice guidelines for primary hip arthroplasty. The prevalence of deep vein thrombosis and pulmonary embolism and the presence of major bleeding events were assessed during hospitalization and at 3 months after discharge and compared between groups. The overall prevalence of thromboembolic events in the hip revision surgery cohort and in the primary hip cohort was 1.62% and 1.35%, respectively (P =.801). The 38.4% of hip revision patients and 20.3% of primary hip patients presented major bleeding events. Thromboembolic disease outcomes with the use of a standardized thromboprophylaxis regimen were similar in both cohorts, regardless of the high variability of hip revision surgery and the increased risk of complications. Implementation of this regimen is recommended in patients requiring joint replacement revision surgery. © The Author(s) 2019.